Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Amortization of Deferred Charges (2018 - 2025)

Collegium Pharmaceutical has reported Amortization of Deferred Charges over the past 7 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Amortization of Deferred Charges at $1.3 million for Q4 2025, down 10.39% from a year ago — trailing twelve months through Dec 2025 was $4.8 million (down 11.89% YoY), and the annual figure for FY2025 was $5.3 million, down 11.22%.
  • Amortization of Deferred Charges for Q4 2025 was $1.3 million at Collegium Pharmaceutical, up from $1.1 million in the prior quarter.
  • Over the last five years, Amortization of Deferred Charges for COLL hit a ceiling of $2.5 million in Q2 2022 and a floor of $779000.0 in Q4 2021.
  • Median Amortization of Deferred Charges over the past 5 years was $1.3 million (2024), compared with a mean of $1.5 million.
  • Biggest five-year swings in Amortization of Deferred Charges: crashed 69.39% in 2021 and later soared 205.91% in 2022.
  • Collegium Pharmaceutical's Amortization of Deferred Charges stood at $779000.0 in 2021, then soared by 205.91% to $2.4 million in 2022, then decreased by 17.62% to $2.0 million in 2023, then fell by 27.46% to $1.4 million in 2024, then fell by 10.39% to $1.3 million in 2025.
  • The last three reported values for Amortization of Deferred Charges were $1.3 million (Q4 2025), $1.1 million (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.